Immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibodies (Abs), have been attracting attention as breakthrough anti-cancer therapies in recent years. This evidence concerns the gene CTLA4 and cancer.